Stock comparison
Genmab A/S
Summit Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.29B
Sector
Healthcare
SMMT
Summit Therapeutics
Market cap
$13.08B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | SMMT | Winner |
|---|---|---|---|
| Warren Buffett | 55C | 9F | GMAB |
| Benjamin Graham | 54C | 40D | GMAB |
| Philip Fisher | 38D | 23F | GMAB |
| Peter Lynch | 15F | 11F | GMAB |
| Joel Greenblatt | 66B | 0F | GMAB |
| Charlie Munger | 58C | 14F | GMAB |
| Terry Smith | 61C | 15F | GMAB |
Side-by-side metrics
| Metric | GMAB | SMMT |
|---|---|---|
| Market cap | $16.29B | $13.08B |
| P/E (TTM) | 6.2x | - |
| EV/EBIT | 12.0x | - |
| ROIC (TTM) | 43.78% | -2.48% |
| Gross margin | 93.88% | 0.0% |
| Net margin | 18.23% | 0.0% |
| Revenue CAGR 5y | -18.45% | - |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs -2.48%+118%
- Gross margin93.88%vs 0.0%+100%
- Net margin18.23%vs 0.0%+100%
- Market cap$16.29Bvs $13.08B+20%
SMMT leads on
- EV/EBIT-vs 12.0x+199%
- P/E (TTM)-vs 6.2x+150%
- Debt / Equity0.0xvs 0.1x+50%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.